Pannysylvania Magazine

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s HPV+ Oropharyngeal Cancer Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of HPV+ Oropharyngeal Cancer, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the HPV+ Oropharyngeal Cancer Market

• The HPV+ Oropharyngeal Cancer market across the 7MM is expected to grow significantly by 2036.

• DelveInsight estimates that the HPV+ Oropharyngeal Cancer market size in the 7MM is expected to increase from nearly USD 1.0 billion in 2022 to approximately USD 1.6 billion by 2036.

• Based on DelveInsight’s assessment, the 7MM accounted for approximately 153,000 incident cases of Head and Neck Squamous Cell Carcinoma (HNSCC) in 2025.

• In the United States, more than 90% of oropharyngeal cancer cases are associated with HPV infection, with HPV16 accounting for nearly 90% of HPV-positive cases.

• Among the site-specific HNSCC cases in the United States, the oropharynx represented the largest disease burden with nearly 20,000 incident cases in 2025.

• Germany accounted for nearly 1,800 regional HPV+ OPSCC cases among EU4 and the United Kingdom in 2025.

• Japan accounted for nearly 4,300 HPV-positive OPSCC cases, including approximately 3,900 HPV16-positive OPSCC cases in 2025.

• KEYTRUDA and OPDIVO remain the primary immune checkpoint inhibitors approved for recurrent or metastatic HNSCC; however, no therapy is currently approved specifically for HPV16-positive cancers.

• Leading HPV+ Oropharyngeal Cancer companies such as PDS Biotechnology, Genmab, Cue Biopharma, Precigen, Immutep, Merus, Bristol Myers Squibb, Merck & Co., and others are actively developing novel therapies expected to enter the market during the forecast period.

• Promising HPV+ Oropharyngeal Cancer therapies include Petosemtamab (MCLA-158), Versamune HPV (PDS0101), CUE-101, PRGN-2009, Eftilagimod alpha, Zanzalintinib, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/human-papillomavirus-positive-oropharyngeal-cancer-market

Key Factors Driving the HPV+ Oropharyngeal Cancer Market

Rising Incidence of HPV-associated Oropharyngeal Cancer

The increasing prevalence of HPV-associated head and neck cancers, particularly HPV16-positive oropharyngeal cancer, continues to drive patient diagnosis and treatment demand. HPV infection has emerged as one of the leading causes of oropharyngeal cancer, especially in developed countries.

Increasing Adoption of Immunotherapy

Checkpoint inhibitors such as KEYTRUDA and OPDIVO have significantly transformed the treatment landscape for recurrent and metastatic head and neck cancers. Continued advances in immunotherapy are expected to improve treatment outcomes and expand therapeutic options.

Growing Development of Therapeutic Vaccines

Therapeutic vaccination has gained considerable momentum, with several HPV-targeted vaccine candidates demonstrating encouraging clinical results. Novel vaccine-based approaches are expected to address significant unmet needs, particularly for HPV16-positive disease.

Robust Late-stage Clinical Pipeline

The HPV+ OPSCC pipeline includes multiple late-stage immunotherapies, bispecific antibodies, therapeutic vaccines, and T-cell-based therapies, reflecting increasing industry investment and strong commercial potential.

HPV+ Oropharyngeal Cancer Competitive Landscape

The HPV+ Oropharyngeal Cancer market continues to evolve rapidly with increasing focus on HPV-targeted immunotherapies and combination treatment strategies.

Current standard treatments include surgery, radiation therapy, chemotherapy, targeted therapy, and immune checkpoint inhibitors including KEYTRUDA and OPDIVO.

Several HPV+ Oropharyngeal Cancer therapies under development include:

• Petosemtamab (Genmab)

• Versamune HPV (PDS Biotechnology)

• CUE-101 (Cue Biopharma)

• PRGN-2009 (Precigen)

• Eftilagimod alpha (Immutep)

• Zanzalintinib

• and others.

These investigational therapies employ diverse mechanisms including HPV-targeted therapeutic vaccination, EGFR/LGR5 bispecific antibody therapy, IL-2-based immune activation, T-cell immunotherapy, and immune checkpoint combinations, with the goal of improving response rates while reducing treatment-related toxicity.

Discover more about therapies set to grab major HPV+ Oropharyngeal Cancer market share @ HPV+ Oropharyngeal Cancer Treatment Landscape

Recent Developments in the HPV+ Oropharyngeal Cancer Market

• In January 2026, PDS Biotechnology announced the issuance of a new patent for PDS0101 (Versamune HPV), extending market exclusivity by an additional 20 years.

• In January 2026, Genmab announced plans to initiate an additional Phase III clinical trial for Petosemtamab, with a potential commercial launch expected in 2027.

• In December 2025, Genmab completed the acquisition of Merus, strengthening its oncology portfolio.

• In November 2025, Merus and Halozyme Therapeutics entered into a global licensing agreement for Halozyme’s ENHANZE drug delivery technology to support the development of subcutaneous Petosemtamab.

• In July 2025, Cue Biopharma reported a new complete response and a confirmed 50% overall response rate in its ongoing Phase I trial evaluating CUE-101 plus pembrolizumab in recurrent/metastatic HPV-positive head and neck cancer.

• According to Precigen’s 2025 corporate update, the Phase II study evaluating PRGN-2009 in newly diagnosed HPV-associated oropharyngeal cancer continues under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.

What is HPV+ Oropharyngeal Cancer?

Human Papillomavirus-positive (HPV+) Oropharyngeal Cancer (OPC) is a subtype of head and neck squamous cell carcinoma (HNSCC) that originates in the oropharynx, including the base of the tongue, tonsils, soft palate, and pharyngeal walls. Persistent infection with high-risk Human Papillomavirus, particularly HPV16, is the primary cause of this malignancy. HPV-positive tumors are biologically distinct from HPV-negative tumors and generally demonstrate better treatment responses and improved survival outcomes. Current treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy; however, no therapy has yet been specifically approved for HPV16-positive cancers, highlighting a significant unmet medical need.

HPV+ Oropharyngeal Cancer Epidemiology Segmentation

The HPV+ Oropharyngeal Cancer epidemiology section provides insights into the historical and current HPV+ Oropharyngeal Cancer patient pool and forecasted trends for the leading markets. The HPV+ Oropharyngeal Cancer market report provides epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Incident Cases of Head and Neck Squamous Cell Carcinoma (HNSCC)

• Total Incident Cases of Oropharyngeal Squamous Cell Carcinoma (OPSCC)

• HPV Status-specific Incident Cases of OPSCC

• HPV16-positive OPSCC Incident Cases

• Stage-specific Incident Cases of HPV+ OPSCC

• Line-wise Treated Cases of HPV+ OPSCC

• Country-specific Incident Cases of HPV+ OPSCC

Scope of the HPV+ Oropharyngeal Cancer Market Report

• Therapeutic Assessment: HPV+ Oropharyngeal Cancer current marketed and emerging therapies

• HPV+ Oropharyngeal Cancer Market Dynamics: Key Market Forecast Assumptions of Emerging HPV+ Oropharyngeal Cancer Drugs and Market Outlook

• Key Companies: PDS Biotechnology, Genmab, Cue Biopharma, Precigen, Immutep, Merus, Bristol Myers Squibb, Merck & Co., and others

• Key Therapies: Petosemtamab (MCLA-158), Versamune HPV (PDS0101), CUE-101, PRGN-2009, Eftilagimod alpha, Zanzalintinib, KEYTRUDA, OPDIVO, and others

• Competitive Intelligence Analysis: SWOT analysis and Market Entry Strategies

• Unmet Needs, KOL’s Views, Analyst’s Views, HPV+ Oropharyngeal Cancer Market Access and Reimbursement

To know more about HPV+ Oropharyngeal Cancer companies working in the treatment market, visit @ HPV+ Oropharyngeal Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

• HPV+ Oropharyngeal Cancer Market Report Introduction

• Executive Summary for HPV+ Oropharyngeal Cancer

• SWOT Analysis of HPV+ Oropharyngeal Cancer

• HPV+ Oropharyngeal Cancer Patient Share (%) Overview at a Glance

• HPV+ Oropharyngeal Cancer Market Overview at a Glance

• HPV+ Oropharyngeal Cancer Background and Overview

• HPV+ Oropharyngeal Cancer Epidemiology and Patient Population

• Country-Specific Patient Population of HPV+ Oropharyngeal Cancer

• HPV+ Oropharyngeal Cancer Current Treatment and Medical Practices

• HPV+ Oropharyngeal Cancer Unmet Needs

• HPV+ Oropharyngeal Cancer Emerging Therapies

• HPV+ Oropharyngeal Cancer Market Outlook

• Country-Wise HPV+ Oropharyngeal Cancer Market Analysis (2022–2036)

• HPV+ Oropharyngeal Cancer Market Access and Reimbursement of Therapies

• HPV+ Oropharyngeal Cancer Market Drivers

• HPV+ Oropharyngeal Cancer Market Barriers

• HPV+ Oropharyngeal Cancer Appendix

• HPV+ Oropharyngeal Cancer Report Methodology

• DelveInsight Capabilities

• Disclaimer

• About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/